Transcutaneous Electrical Acupoint Stimulation(TEAS) for Hepatic and Renal Dysfunction After Pneumoperitoneum

Effect of Transcutaneous Electrical Acupoint Stimulation(TEAS) on the Hepatic and Renal Function Impaired by Pneumoperitoneum: a Prospective, Randomized Controlled Trial

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02013596

Acronym

TRIP

Enrollment

168

Registered

2013-12-17

Start date

2013-12-31

Completion date

2015-12-31

Last updated

2016-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatic Dysfunction Transient, Renal Function Disorder

Keywords

hepatic dysfunction, renal dysfunction, pneumoperitoneum, Transcutaneous electric stimulation

Brief summary

The purpose of this study is to compare the effect of TEAS pretreatment and treatment on hepatic and renal dysfunction induced by pneumoperitoneum in patients undergoing laparoscopic surgeries.

Detailed description

Patients were randomly assigned to three groups, control group and two intervention groups, receiving TEAS before and after general anesthesia induction respectively. TEAS was given through electrodes attached to acupoints. The time for TEAS was 30min. Venous blood samples were collected before and 20min after pneumoperitoneum. Hepatic and renal function index including AST, ALT, ALP, BUN, Cr were measured.

Interventions

OTHERTEAS pretreatment

Electric stimulation was given through electrode attached to specific acupoints for 30mins before anesthesia induction

OTHERTEAS treatment

Transcutaneous Electrical Acupoint Stimulation was given to the patient at the same time of the start of anesthesia induction for 30mins

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Age\>18yrs,\<60yrs； * ASA 1-2； * Scheduled for laparoscopic surgery under general anesthesia； * Informed consented

Exclusion criteria

* Patients with hepatic or renal dysfunction； * Patients with severe hypertension or cardiac dysfunction； * Patients with severe pulmonary disease； * Patients with hemoglobin\<100g/L

Design outcomes

Primary

Measure	Time frame	Description
Incidence of renal or hepatic dysfunction	20min after pneumoperitoneum	percentage of patients with renal or hepatic dysfunction

Secondary

Measure	Time frame	Description
Change of hepatic function	20min after pneumoperitoneum	the increase of hepatic ALT and AST after pneumoperitoneum
Change of renal function	20min after pneumoperitoneum	Change of BUN and Cr after pneumoperitoneum

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026